Latest News about JNJ
Recent news which mentions JNJ
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
February 01, 2025
Tickers
JNJ
From Motley Fool
From Motley Fool
Johnson & Johnson's Options Frenzy: What You Need to Know
January 30, 2025
Tickers
JNJ
From Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
January 29, 2025
From Benzinga
From Benzinga
From Benzinga
Georgia Rep. Marjorie Taylor Greene Bought Up to $45K Worth of Johnson & Johnson Stock
January 28, 2025
From Benzinga
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 27, 2025
From Benzinga
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
January 25, 2025
From Motley Fool
From Motley Fool
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?
January 23, 2025
From Motley Fool
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
January 23, 2025
From Benzinga
Tickers
JNJ
From Motley Fool
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run
January 22, 2025
From Benzinga
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
January 22, 2025
From Benzinga
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
January 22, 2025
Tickers
JNJ
From Motley Fool
Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday?
January 22, 2025
From Benzinga
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
January 22, 2025
From Benzinga
US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch
January 22, 2025
From Benzinga
Earnings Scheduled For January 22, 2025
January 22, 2025
From Benzinga
Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
January 22, 2025
From Benzinga
From Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
January 22, 2025
From Benzinga
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
January 21, 2025
From Benzinga
From Benzinga
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
January 21, 2025
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.